Literature DB >> 17316612

Dorsal column sensory axons lack TrkC and are not rescued by local neurotrophin-3 infusions following spinal cord contusion in adult rats.

K Adam Baker1, Shojiro Nakashima, Theo Hagg.   

Abstract

By reducing the progressive degeneration and disconnection of axons following spinal cord injury the functional outcome should improve. After direct transection of dorsal column sensory axons, neurotrophin-3 (NT-3) treatment can reduce degeneration and promote regeneration of the proximal stumps. Here, we tested in adult rats whether NT-3 infusion at the site of a moderate T9 spinal cord contusion would rescue sensory connections to the gracile nucleus in the medulla. Sensory projections were anterogradely traced bilaterally with injections of cholera toxin B (CTB) into the sciatic nerve 3 days before analysis. Seven days after the contusion plus intrathecal (subarachnoid) vehicle infusion as a control, the CTB-positive innervation of the gracile nucleus was reduced to approximately 25% of sham-operated rats. Intrathecal infusion of 10 microg/day of NT-3 did not affect this reduced innervation. To ensure good tissue penetration and high concentrations of NT-3 early after the injury, other rats received intraparenchymal infusions of vehicle or NT-3 near the injury site starting 2 days before until 7 days after the injury. This NT-3 treatment also did not affect the reduced innervation. This suggests that local NT-3 treatments cannot protect sensory axons from secondary degeneration after a contusive spinal cord injury. These results are likely because TrkC is not present in axons of the dorsal columns or gracile nucleus, or in other dorsal column cell types, even after the contusion. Together with published results, our data suggest that NT-3 is a peripherally--but not centrally--derived neurotrophic factor for sensory neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316612     DOI: 10.1016/j.expneurol.2007.01.018

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

Review 1.  Combinatorial strategies with Schwann cell transplantation to improve repair of the injured spinal cord.

Authors:  Jenny Fortun; Caitlin E Hill; Mary Bartlett Bunge
Journal:  Neurosci Lett       Date:  2009-01-17       Impact factor: 3.046

2.  Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions.

Authors:  Kevin P Horn; Sarah A Busch; Alicia L Hawthorne; Nico van Rooijen; Jerry Silver
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

3.  Intrathecal Acetyl-L-Carnitine Protects Tissue and Improves Function after a Mild Contusive Spinal Cord Injury in Rats.

Authors:  Eric E Ewan; Theo Hagg
Journal:  J Neurotrauma       Date:  2015-12-02       Impact factor: 5.269

4.  Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats.

Authors:  Shojiro Nakashima; Sheila A Arnold; Edward T Mahoney; Srinivas D Sithu; Y Ping Zhang; Stanley E D'Souza; Christopher B Shields; Theo Hagg
Journal:  J Neurosci       Date:  2008-07-16       Impact factor: 6.167

5.  Dorsal column sensory axons degenerate due to impaired microvascular perfusion after spinal cord injury in rats.

Authors:  Johongir M Muradov; Eric E Ewan; Theo Hagg
Journal:  Exp Neurol       Date:  2013-08-23       Impact factor: 5.330

Review 6.  Sustained delivery of neurotrophic factors to treat spinal cord injury.

Authors:  Aikeremujiang Muheremu; Li Shu; Jing Liang; Abudunaibi Aili; Kan Jiang
Journal:  Transl Neurosci       Date:  2021-11-30       Impact factor: 1.757

7.  Receptor tyrosine kinases: molecular switches regulating CNS axon regeneration.

Authors:  Vasanthy Vigneswara; Sarina Kundi; Zubair Ahmed
Journal:  J Signal Transduct       Date:  2012-07-16

Review 8.  The Dorsal Column Lesion Model of Spinal Cord Injury and Its Use in Deciphering the Neuron-Intrinsic Injury Response.

Authors:  Callan L Attwell; Mike van Zwieten; Joost Verhaagen; Matthew R J Mason
Journal:  Dev Neurobiol       Date:  2018-05-11       Impact factor: 3.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.